Table 1:

Baseline characteristics of the training and validation sets stratified with LNAS risk-score

	Training cohort (N=210)				Validation cohort (N=39)
	Total	Low Risk	High Risk	p-value	Total	Low Risk	High Risk	p-value
Sex
Male	161(77)	81(77)	80(76)	0.87	35(90)	17(90)	18(90)	1
Female	49(23)	24(23)	25(24)		4(10)	2(10)	2(10)
Tumor Size
<45mm	99(47)	44(42)	55(52)	0.14	18(46)	9(47)	9(45)	0.88
≥45mm	104(50)	57(54)	47(45)		21(54)	10(53)	11(55)
Undefined	7(3)	4(4)	3(3)		0(0)	0(0)	0(0)
Differentiation
Well	22(10)	11(11)	11(11)	0.91	17(44)	6(32)	11(55)	0.65
Moderate	148(71)	76(72)	72(69)		9(23)	4(21)	5(25)
Poor	29(14)	14(13)	15(14)	0.9	13(33)	9(47)	4(20)	0.06
Undefined	11(5)	4(4)	7(7)		0(0)	0(0)	0(0)
T category
T1	44(21)	22(21)	22(21)	0.69	3(8)	3(16)	0(0)	0.27
T2	33(16)	15(14)	18(17)		3(8)	2(10)	1(5)
T3	119(57)	63(60)	56(53)	0.73	32(82)	14(74)	18(90)	0.06
T4	12(6)	4(4)	8(8)	0.3	1(2)	0(0)	1(5)	0.04
Undefined	2(1)	1(1)	1(1)		0(0)	0(0)	0(0)
Lymph Node metastasis
Absent	67(32)	42(40)	25(24)	0.19	7(18)	6(32)	1(5)	0.03
Present	143(68)	63(60)	80(76)		32(82)	13(68)	19(95)
Distant Metastasis
Present	189(90)	91(87)	98(93)	0.1	36(92)	18(95)	0(0)	0.003
Absent	21(10)	14(13)	7(7)		3(8)	1(5)	2(100)
TNM stage
Stage I	41(20)	26(25)	15(14)	0.11	4(10)	3(16)	1(5)	0.85
Stage II	45(21)	21(20)	24(23)		5(13)	4(21)	1(5)
Stage III	101(48)	43(41)	58(55)	0.02	27(69)	11(58)	16(80)	0.19
Stage IV	21(10)	14(13)	7(7)	0.8	3(8)	1(5)	2(10)	0.27
Undefined	2(1)	1(1)	1(1)		0(0)	0(0)	0(0)
Lymphatic vessel Invasion
Absent	56(27)	35(33)	21(20)	0.02	18(46)	8(42)	10(50)	0.62
Present	151(72)	68(65)	83(79)		21(54)	11(58)	10(50)
Undefined	3(1)	2(2)	1(1)		0(0)	0(0)	0(0)
Venous Invasion
Absent	128(61)	61(58)	67(64)	0.39	15(38)	9(47)	6(30)	0.26
Present	80(38)	43(41)	37(35)		24(62)	10(53)	14(70)
Undefined	2(1)	1(1)	1(1)		0(0)	0(0)	0(0)